Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIMSPRO for Bladder Dysfunction in SPMS
NCT01228396Phase 2Unknown
- Sponsor
- Daval International Ltd
- Start
- May 2009
- Primary completion
- May 2011
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AIMSPRO in secondary-progressive multiple sclerosis (SPMS), sponsored by Daval International Ltd. Status: unknown.
02
Drugs
AIMSPRO
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT01228396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01228396.